

Annual Conference on Haematology and Blood Disorder Conference June 15-16, 2020 London, UK

Belhadi Kamilia

Department of Pediatrics, University Hospital of Batna, Algeria, E-mail: belhadikamilia@yahoo.fr


Haematology, also spelled hematology, is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. Such diseases might include hemophilia, blood clots, other bleeding disorders and blood cancers such as leukemia, multiple myeloma, and lymphoma. The laboratory work that goes into the study of blood is frequently performed by a medical technologist or medical laboratory scientist.

The [hematology diagnostics](#) marketplace was esteemed at US\$ 3,167.2 million in 2017 and predictable to scope US\$ 5,288.3 million by 2026 at a CAGR of 5.9% throughout the prognostication period from 2018 to 2026.

Globally haematology diagnostics marketplace scope was valued at USD 5.96 billion in 2017. It is predicted to increase at a CAGR of 5.85% over the estimate retro. Aspects such as cumulative pervasiveness of blood disorders tied with collective consciousness about these ailments, and presence of classy & cutting-edge technologies are projected to boost the [market progress](#).

Conferring to an artefact issued by Bristol-Myers Squibb, approximately 1 million novel cases of blood malignancy are anticipated to be spotted by 2020, that is estimated to reason for nearly 6.0% of all new-fangled tumors. Besides, a momentous number of the world inhabitants have diverse hemoglobinopathies. High incidence of blood ailments, such that thalassemia is expected to kick the demand for hematology testing.

Global hematology diagnostics market size, by end-use, 2014 - 2025 (USD Billion)



CME Accredited [Hematologists 2020](#) will be organized by EuroSciCon Ltd which is comprised of 3000+ Global Events with over 1000+ Conferences, 1200+ Symposiums and 1200+ Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe. EuroSciCon Ltd through its international conferences provides an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings.



Link: <http://hematology.euroscicon.com/>

The advanced investigations in the biomedical segment, exclusively in emerging countries, will boost marketplace development in flow cytometry. Aggregate of radiologists and intensifying attention on the inhibition, and primary diagnosis of ailments will drive the number of medical imaging measures like MRI and CT assessments in hospitals and ASCs across limitless countries. These are predictable to be the chief progress handlers for the global medical imaging components market.

Global market of haematology diagnostics is increasing at a CAGR of 5.9% for the retro from 2018 to 2026

The haematology analyzer sector displays rewarding progress with boosted applications in the diagnostics trade based on the product type.

An increasing number of diagnostic centers, availability of automated analysers with enhanced applications, and increasing test volumes will contribute to the overall growth of the haematology diagnostics market

Major players in this vertical are Abbott Laboratories, Bio-Rad Laboratories, Inc., Siemens Healthineers, [Mindray Medical International Limited](#), Danaher Corporation, Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Drew Scientific, Sysmex Corporation, EKF Diagnostics, Boule Diagnostics, HORIBA, Diatron MI Zrt. and others

The biotechnology industry is marked by high competition and so is the [NGS market](#) for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.

Samuel George

Program Coordinator | [Haematology 2020](#)